High‐intensity and moderate‐intensity statin use. A new perspective on LDL‐C and/or non‐HDL‐C treatment goals. In persons at high ASCVD risk receiving the maximum tolerated statin who have a less‐than‐anticipated therapeutic response, addition of a nonstatin LDL lowering agent may be...